TCHP

DRUG3 trials

Sponsors

Guangdong Provincial People's Hospital, Fudan University, Georgetown University

Conditions

Cancer Related Cognitive DeclineHER2-Positive Breast CancerHER2-positive Breast CancerNon-metastatic Breast Cancer

Phase 1

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

RecruitingNCT05256745

Georgetown UniversityCancer Related Cognitive Decline, Non-metastatic Breast Cancer

Start: 2023-06-06End: 2026-12-31Target: 48Updated: 2025-12-24

Phase 2

TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer

Guangdong Provincial People's HospitalHER2-Positive Breast Cancer

Start: 2019-09-17End: 2022-09-17Target: 200Updated: 2019-09-19

Unknown Phase

Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

RecruitingNCT04281641

Fudan UniversityHER2-positive Breast Cancer

Start: 2020-04-21End: 2030-04-30Target: 94Updated: 2020-05-04

Related Papers

RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE).

Journal of Clinical Oncology2024-05-29

Abstract PO5-01-05: An Open-label, Single-center Study Assessing the Efficacy of PH-based Regimen as Neoadjuvant Therapy for HER2-positive Early-stage Breast Cancer: Integrating Genomic Features and Functional Imaging

Cancer Research2024-05-02